BridgeBio Adds Financial Runway Ahead Of Expected ATTR-CM Approval

Biotech gets $500m upon FDA approval in exchange for 5% sales royalty on acoramidis, which is expected to compete with Pfizer’s Vyndamax. The agreement also pushes debt payout to 2029.